June 26, 2026 New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; multiple dose assessment underway…
June 26, 2026
New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; multiple dose assessment underway
New program announced as HMB-003, a potent peptide plasmin inhibitor with a durable half-life designed as a novel antifibrinolytic to reduce bleeding across multiple settings; initiating first-in-human studies in 2H 2026 and preparing for studies in heavy menstrual bleeding in 2027
Long-term extension (LTE) data for sutacimig demonstrate sustained reduction in annualized treated bleeding rate (ATBR) in Glanzmann thrombasthenia (GT)
Sutacimig granted FDA Breakthrough Therapy and EMA Priority Medicines (PRIME)
designations; Phase 3 initiation planned 2H 2026
Total of nine presentations reflect the breadth and momentum of Hemab’s pipeline of assets designed to address critical gaps in the treatment of multiple coagulation disorders
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced nine presentations showcasing progress from multiple pipeline programs at the upcoming International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France, on July 11-15, 2026.
“People living with serious coagulation disorders remain profoundly underserved, with few targeted preventive treatment options, leaving them to face the relentless burden of unpredictable, disruptive bleeding, with substantial medical, social, psychological, and quality-of-life impact,” said Benny Sørensen, MD, PhD, CEO of Hemab. “We’re advancing three programs with the potential to change that. We are progressing sutacimig to Phase 3 in GT, strengthening the clinical validation of HMB-002 in VWD, and introducing HMB-003, a novel long-acting peptide-based inhibitor of plasmin, a proven therapeutic target in coagulation medicine, central to bleeding in conditions ranging from heavy menstrual bleeding and hereditary hemorrhagic telangiectasia to peri-operative bleeding management. Our presentations at ISTH 2026 demonstrate our momentum and progress across our pipeline.”
For sutacimig, Phase 2 LTE data show sustained reductions in ATBR in GT and describe successful use in the surgical setting and are complemented by real-world and natural-history analyses that help quantify disease burden. Additionally, preclinical data for sutacimig will be presented supporting expansion into Factor VII deficiency (FVIID) where a Phase 2b study is currently in progress. For HMB-002, new first-in-human data validate the approach of simply increasing VWF and FVIII in VWD with durable subcutaneous dosing, and a multiple dose assessment is underway. For HMB-003, preclinical findings describe a novel fatty acid conjugated peptide antifibrinolytic designed for potent plasmin inhibition with durable half-life and subcutaneous dosing allowing the potential for use in multiple high-unmet-need bleeding conditions including heavy menstrual bleeding.
Presentation Highlights and Details – The abstracts are now available through the ISTH conference website
Sutacimig
Sutacimig showed sustained prophylaxis in GT (meaningful reduction in ATBR and high-intensity treatment events and use in surgical setting) in LTE portion of ongoing Phase 2 trial, with real-world and natural-history data underscoring the unmet need, and preclinical validation supporting expansion into FVIID with a Phase 2 proof-of-concept study underway; data expected late 2026 or early 2027.
Presentation Number:OC 57.3
Format: Oral
Title: Sutacimig Prophylaxis in Glanzmann Thrombasthenia: Results from a Phase 2 Long-Term Extension
Date and Time: July 14, 2026, 10:00 AM - 10:15 AM CEST
Presentation Number:OC 12.4
Format: Oral
Title: Elucidating Sutacimig’s Dual Mechanism in Factor VII Deficiency: TF-Pathway Enhancement via FVIIa Accumulation as the Significant Driver of Hemostatic Activity
Date and Time: July 12, 2026, 10:00 AM - 10:15 AM CEST
Presentation Number:PB3513
Format: Poster
Title: Persistent Weekly Bleeding Burden Across the Lifespan in Glanzmann Thrombasthenia: Analysis of the GT360 Patient Survey
Date and Time: July 14, 2026, 1:45 PM CEST
Presentation Number:PB3523
Format: Poster
Title: Elevated Depression Prevalence and Psychological Burden Associated with Bleeding Frequency in Glanzmann Thrombasthenia
Date and Time: July 14, 2026, 1:45 PM CEST
Presentation Number:PB3495
Format: Poster
Title: Substantial Bleeding Burden and Limited Prophylaxis Use in Glanzmann Thrombasthenia: Prospective Real-World Data from ATHN Transcends
Date and Time: July 14, 2026, 1:45 PM CEST
HMB-002
HMB-002’s first-in-human data from an ongoing Phase 1/2 clinical trial support a non-replacement subcutaneous approach that elevates endogenous VWF and FVIII, with sustained hemostatic elevations and no thromboembolic events observed; multiple dose assessment is currently underway to enable a potential new prophylaxis paradigm in VWD.
Presentation Number:OC 12.5
Format: Oral
Title: First-in-human investigation of HMB-002: a subcutaneous antibody for prophylactic management of Von Willebrand disease
Date and Time: July 12, 2026, 10:15 AM - 10:30 AM CEST
HMB-003
HMB-003 is a potent subcutaneous plasmin inhibitor with a durable half-life that blocks fibrinolysis independently of the plasminogen activation pathway (tPA or uPA). HMB-003 inhibited fibrinolysis with greater potency than tranexamic acid in a human whole-blood flow model and demonstrated long half-life in preclinical models, supporting infrequent dosing with potential across multiple high-unmet-need conditions; first-in-human studies are planned for the second half of 2026.
Presentation Number:OC 05.1
Format: Oral
Title: A long-acting peptide plasmin inhibitor with extended antifibrinolytic activity enabling once-per-cycle subcutaneous treatment for heavy menstrual bleeding: Preclinical development of HMB-003
Date and Time: July 11, 2026, 1:00 PM - 1:15 PM CEST
Presentation Number:OC 09.5
Format: Oral
Title: HMB-003, a long-acting peptide plasmin inhibitor, potently inhibits fibrinolysis and localizes with fibrin in a human whole blood microfluidic flow model
Date and Time: July 11, 2026, 2:00 PM - 2:15 PM CEST